[go: up one dir, main page]

CY1123963T1 - Καινοτομα πολυμερικα προφαρμακα hgh - Google Patents

Καινοτομα πολυμερικα προφαρμακα hgh

Info

Publication number
CY1123963T1
CY1123963T1 CY20211100235T CY211100235T CY1123963T1 CY 1123963 T1 CY1123963 T1 CY 1123963T1 CY 20211100235 T CY20211100235 T CY 20211100235T CY 211100235 T CY211100235 T CY 211100235T CY 1123963 T1 CY1123963 T1 CY 1123963T1
Authority
CY
Cyprus
Prior art keywords
innovative
prodrugs
polymeric
growth hormone
polymeric hgh
Prior art date
Application number
CY20211100235T
Other languages
English (en)
Inventor
Thomas Kurpiers
Harald Rau
Evelyn Exner
Steen Jensen
Grethe Nørskov Rasmussen
Torben Lessmann
Thomas Wegge
Alina HERMANN
Nina SCHUBERT
Anna SPLANEMANN
Joachim Zettler
Original Assignee
Ascendis Pharma Endocrinology Division A/S
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=51951624&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CY1123963(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Ascendis Pharma Endocrinology Division A/S filed Critical Ascendis Pharma Endocrinology Division A/S
Publication of CY1123963T1 publication Critical patent/CY1123963T1/el

Links

Classifications

    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01G—HORTICULTURE; CULTIVATION OF VEGETABLES, FLOWERS, RICE, FRUIT, VINES, HOPS OR SEAWEED; FORESTRY; WATERING
    • A01G17/00—Cultivation of hops, vines, fruit trees, or like trees
    • A01G17/005—Cultivation methods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/27—Growth hormone [GH], i.e. somatotropin
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01G—HORTICULTURE; CULTIVATION OF VEGETABLES, FLOWERS, RICE, FRUIT, VINES, HOPS OR SEAWEED; FORESTRY; WATERING
    • A01G2/00—Vegetative propagation
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01G—HORTICULTURE; CULTIVATION OF VEGETABLES, FLOWERS, RICE, FRUIT, VINES, HOPS OR SEAWEED; FORESTRY; WATERING
    • A01G7/00—Botany in general
    • A01G7/06—Treatment of growing trees or plants, e.g. for preventing decay of wood, for tingeing flowers or wood, for prolonging the life of plants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/20—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/06—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/61—Growth hormone [GH], i.e. somatotropin
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
    • C08G65/00—Macromolecular compounds obtained by reactions forming an ether link in the main chain of the macromolecule
    • C08G65/02—Macromolecular compounds obtained by reactions forming an ether link in the main chain of the macromolecule from cyclic ethers by opening of the heterocyclic ring
    • C08G65/32—Polymers modified by chemical after-treatment
    • C08G65/329—Polymers modified by chemical after-treatment with organic compounds
    • C08G65/334—Polymers modified by chemical after-treatment with organic compounds containing sulfur
    • C08G65/3348—Polymers modified by chemical after-treatment with organic compounds containing sulfur containing nitrogen in addition to sulfur
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
    • C08G2650/00—Macromolecular compounds obtained by reactions forming an ether link in the main chain of the macromolecule
    • C08G2650/02—Macromolecular compounds obtained by reactions forming an ether link in the main chain of the macromolecule characterized by the type of post-polymerisation functionalisation
    • C08G2650/06—Epoxy-capping

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Endocrinology (AREA)
  • Organic Chemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Botany (AREA)
  • Environmental Sciences (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Forests & Forestry (AREA)
  • Ecology (AREA)
  • Biodiversity & Conservation Biology (AREA)
  • Urology & Nephrology (AREA)
  • Polymers & Plastics (AREA)
  • Developmental Biology & Embryology (AREA)
  • Wood Science & Technology (AREA)
  • Toxicology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Dermatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)

Abstract

Η παρούσα εφεύρεση αναφέρεται σε ένα πολυμερικό προφάρμακο της ανθρώπινης αυξητικής ορμόνης και σε ξηρές, υγρές και ανασυσταθείσες φαρμακευτικές συνθέσεις που περιέχουν το εν λόγω προφάρμακο. Επιπλέον αναφέρεται στη χρήση τους ως φαρμακευτικά σκευάσματα για τη θεραπεία νοσημάτων τα οποία μπορούν να θεραπευτούν με την αυξητική ορμόνη και σε μεθόδους θεραπείας. Αναφέρεται επίσης σε μεθόδους εφαρμογής τέτοιων πολυμερικών προφαρμάκων ανθρώπινης αυξητικής ορμόνης ή φαρμακευτικών συνθέσεων.
CY20211100235T 2014-11-18 2021-03-18 Καινοτομα πολυμερικα προφαρμακα hgh CY1123963T1 (el)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP14193603 2014-11-18
PCT/EP2015/076813 WO2016079114A1 (en) 2014-11-18 2015-11-17 Novel polymeric hgh prodrugs
EP15797642.4A EP3237014B1 (en) 2014-11-18 2015-11-17 Novel polymeric hgh prodrugs

Publications (1)

Publication Number Publication Date
CY1123963T1 true CY1123963T1 (el) 2022-05-27

Family

ID=51951624

Family Applications (2)

Application Number Title Priority Date Filing Date
CY20211100235T CY1123963T1 (el) 2014-11-18 2021-03-18 Καινοτομα πολυμερικα προφαρμακα hgh
CY2022013C CY2022013I1 (el) 2014-11-18 2022-05-12 Καινοτομα πολυμερικα προφαρμακα hgh

Family Applications After (1)

Application Number Title Priority Date Filing Date
CY2022013C CY2022013I1 (el) 2014-11-18 2022-05-12 Καινοτομα πολυμερικα προφαρμακα hgh

Country Status (28)

Country Link
US (3) US10799563B2 (el)
EP (3) EP3653227B9 (el)
JP (5) JP6783782B2 (el)
KR (2) KR20230152187A (el)
AU (3) AU2015348633C1 (el)
BR (1) BR112017009798A8 (el)
CA (1) CA2968282A1 (el)
CY (2) CY1123963T1 (el)
DK (2) DK3653227T5 (el)
ES (2) ES2947818T3 (el)
FI (2) FI3237014T3 (el)
FR (1) FR22C1029I2 (el)
HR (1) HRP20210400T4 (el)
HU (2) HUE053855T2 (el)
IL (2) IL307773A (el)
LT (2) LT3653227T (el)
LU (1) LUC00256I2 (el)
MX (2) MX2017006113A (el)
NL (1) NL301172I2 (el)
NO (1) NO2022014I1 (el)
PL (1) PL3653227T6 (el)
PT (1) PT3653227T (el)
RS (1) RS61734B2 (el)
RU (1) RU2718664C2 (el)
SG (2) SG10202105511RA (el)
SI (1) SI3653227T1 (el)
SM (1) SMT202100172T1 (el)
WO (1) WO2016079114A1 (el)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HUE029926T2 (en) * 2008-04-29 2017-04-28 Ascendis Pharma Growth Disorders Div As Pegylated recombinant human growth hormone compounds
RU2012129674A (ru) 2009-12-15 2014-01-27 Аспендис Фарма Ас Композиция гормона роста
WO2016079114A1 (en) 2014-11-18 2016-05-26 Ascendis Pharma Growth Disorders Division A/S Novel polymeric hgh prodrugs
EP3988083A1 (en) 2014-11-21 2022-04-27 Ascendis Pharma Endocrinology Division A/S Long-acting growth hormone dosage forms
SI3518930T1 (sl) 2016-09-29 2023-06-30 Ascendis Pharma Growth Disorders A/S Kombinirana terapija z agonisti CNP s kontroliranim sproščanjem
JP7490563B2 (ja) 2018-03-28 2024-05-27 アセンディス ファーマ オンコロジー ディヴィジョン エー／エス Ｉｌ－２コンジュゲート
US20210008168A1 (en) 2018-03-28 2021-01-14 Ascendis Pharma A/S Conjugates
CA3125541A1 (en) 2019-01-04 2020-07-09 Ascendis Pharma Oncology Division A/S Minimization of systemic inflammation
CA3125488A1 (en) 2019-01-04 2020-07-09 Ascendis Pharma Oncology Division A/S Induction of sustained local inflammation
PH12021551591A1 (en) 2019-01-04 2022-04-18 Ascendis Pharma Oncology Div A/S Conjugates of pattern recognition receptor agonists
JP2022516314A (ja) 2019-01-04 2022-02-25 アセンディス ファーマ オンコロジー ディヴィジョン エー／エス 自然免疫アゴニストのための持続性局所性薬物レベル
EP3934625A1 (en) 2019-03-04 2022-01-12 Ascendis Pharma Endocrinology Division A/S Long-acting growth hormone dosage forms with superior efficacy to daily somatropin
EP4161956A1 (en) 2020-06-03 2023-04-12 Ascendis Pharma Oncology Division A/S Il-2 sequences and uses thereof
AU2022246997A1 (en) 2021-04-01 2023-09-28 Ascendis Pharma A/S Use of long-acting growth hormone for treating inflammation-induced diseases

Family Cites Families (72)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4179337A (en) 1973-07-20 1979-12-18 Davis Frank F Non-immunogenic polypeptides
US4342832A (en) 1979-07-05 1982-08-03 Genentech, Inc. Method of constructing a replicable cloning vehicle having quasi-synthetic genes
IL78930A0 (en) 1985-07-29 1986-09-30 Abbott Lab Lyophilized emulsion compositions for parenteral administration
US5057417A (en) 1987-06-12 1991-10-15 Genentech, Inc. Compositions and methods for the synthesis of growth hormone receptor and growth hormone binding protein
US5073627A (en) 1989-08-22 1991-12-17 Immunex Corporation Fusion proteins comprising GM-CSF and IL-3
US5179080A (en) 1989-08-31 1993-01-12 Clinical Homecare, Corp. Formulations containing growth hormone and nutritional supplements, and methods of treating malnutrition in chronic lung disease
JPH0531189A (ja) 1991-01-16 1993-02-09 Takeda Chem Ind Ltd ２室型注射器
IL99120A0 (en) 1991-08-07 1992-07-15 Yeda Res & Dev Multimers of the soluble forms of tnf receptors,their preparation and pharmaceutical compositions containing them
IL101007A (en) 1992-02-18 1997-08-14 Pharmos Ltd Dry stable compositions prepared by lyophilization
CA2146559A1 (en) 1992-10-23 1994-05-11 Melanie K. Spriggs Methods of preparing soluble, oligomeric proteins
SE9303918L (sv) 1993-11-26 1995-05-22 Hans Lundstroem Anordning vid en box
ZA966075B (en) 1995-07-27 1998-01-19 Genentech Inc Protein formulation.
US5908621A (en) 1995-11-02 1999-06-01 Schering Corporation Polyethylene glycol modified interferon therapy
KR100236771B1 (ko) 1997-04-01 2000-02-01 성재갑 히아루론산을 이용한 약물의 서방성 미세입자 제형
TW517067B (en) 1996-05-31 2003-01-11 Hoffmann La Roche Interferon conjugates
US6011197A (en) * 1997-03-06 2000-01-04 Infigen, Inc. Method of cloning bovines using reprogrammed non-embryonic bovine cells
US5971953A (en) 1998-01-09 1999-10-26 Bachynsky; Nicholas Dual chamber syringe apparatus
EP1037649B1 (en) 1997-12-17 2009-09-30 Enzon, Inc. Polymeric prodrugs of amino- and hydroxyl-containing bioactive agents
US6624142B2 (en) 1997-12-30 2003-09-23 Enzon, Inc. Trimethyl lock based tetrapartate prodrugs
US6284282B1 (en) 1998-04-29 2001-09-04 Genentech, Inc. Method of spray freeze drying proteins for pharmaceutical administration
PE20010288A1 (es) 1999-07-02 2001-03-07 Hoffmann La Roche Derivados de eritropoyetina
US6413507B1 (en) 1999-12-23 2002-07-02 Shearwater Corporation Hydrolytically degradable carbamate derivatives of poly (ethylene glycol)
IL152360A0 (en) 2000-04-19 2003-05-29 Genentech Inc Sustained release formulations
EP1243276A1 (en) 2001-03-23 2002-09-25 Franciscus Marinus Hendrikus De Groot Elongated and multiple spacers containing activatible prodrugs
MXPA04004809A (es) 2001-11-20 2004-08-11 Pharmacia Corp Conjugados de hormona de crecimiento humana modificada quimicamente.
US20030171285A1 (en) 2001-11-20 2003-09-11 Finn Rory F. Chemically-modified human growth hormone conjugates
US7144978B2 (en) 2002-01-15 2006-12-05 Pan Asia Bio Co., Ltd. Multidrop tree branching functional polyethylene glycol, methods of preparing and using same
AU2003256038A1 (en) 2002-08-30 2004-03-19 Ramot At Tel Aviv University Ltd. Self-immolative dendrimers releasing many active moieties upon a single activating event
EP1560599A1 (en) 2002-11-14 2005-08-10 Syntarga B.V. Prodrugs built as multiple self-elimination-release spacers
EP1562634B1 (en) 2002-11-15 2006-08-23 F. Hoffmann-La Roche Ag Positional isomers of pegylated interferon alpha 2a
US20040142870A1 (en) 2002-11-20 2004-07-22 Finn Rory F. N-terminally monopegylated human growth hormone conjugates, process for their preparation, and methods of use thereof
US7947261B2 (en) 2003-05-23 2011-05-24 Nektar Therapeutics Conjugates formed from polymer derivatives having particular atom arrangements
SI2932981T1 (sl) 2003-09-19 2021-11-30 Novo Nordisk A/S Albumin-vezavni derivati GLP-1
EP1525890A1 (en) 2003-10-02 2005-04-27 Complex Biosystems GmbH Protein-Proteophore complexes
WO2005034988A1 (en) 2003-10-10 2005-04-21 Novo Nordisk A/S Long-acting molecules in sustained release formulations
GB0329825D0 (en) 2003-12-23 2004-01-28 Celltech R&D Ltd Biological products
WO2005099768A2 (en) 2004-03-23 2005-10-27 Complex Biosystems Gmbh Polymeric prodrug with a self-immolative linker
EP1579873A1 (en) 2004-03-23 2005-09-28 Complex Biosystems GmbH Polymeric prodrugs
EP1625855A1 (en) 2004-08-13 2006-02-15 Complex Biosystems GmbH Polymeric prodrug with a self-immolative linker
US7968085B2 (en) 2004-07-05 2011-06-28 Ascendis Pharma A/S Hydrogel formulations
BRPI0519430A2 (pt) 2004-12-22 2009-02-10 Ambrx Inc hormânio do crescimento humano modificado
SG161210A1 (en) 2004-12-22 2010-05-27 Ambrx Inc Methods for expression and purification of recombinant human growth hormone
MX2007007587A (es) 2004-12-22 2007-12-11 Ambrx Inc Formulaciones de la hormona del crecimiento humano que comprenden un aminoacido codificado de manera no natural.
US7959600B2 (en) 2004-12-30 2011-06-14 Byeong S. Chang Container closure delivery system
WO2006076471A2 (en) 2005-01-12 2006-07-20 Nobex Corporation Bnp conjugates and methods of use
WO2006084888A2 (en) 2005-02-10 2006-08-17 Novo Nordisk A/S C-terminally pegylated growth hormones
US20060233740A1 (en) * 2005-03-23 2006-10-19 Bossard Mary J Conjugates of an hGH moiety and a polymer
MX2007015676A (es) 2005-06-15 2008-02-20 Novo Nordisk Healthcare Ag Conjugacion de la hormona de crecimiento mediada por transglutaminasa.
GB2427360A (en) 2005-06-22 2006-12-27 Complex Biosystems Gmbh Aliphatic prodrug linker
BRPI0615351A2 (pt) 2005-08-30 2011-05-17 Novo Nordisk Healthcare Ag formulações lìquidas de hormÈnio do crescimento peguilado
ES2390286T3 (es) 2005-12-16 2012-11-08 Nektar Therapeutics Conjugados poliméricos de GLP-1
KR102109867B1 (ko) 2006-01-24 2020-05-13 안선 바이오파르마, 아이엔씨. 고분자 미소 구체들의 조제를 위한 기술
US8450269B2 (en) 2006-02-03 2013-05-28 Prolor Biotech Ltd. Long-acting growth hormone and methods of producing same
GB0700523D0 (en) 2007-01-11 2007-02-21 Insense Ltd The Stabilisation Of Proteins
WO2008148839A2 (en) 2007-06-08 2008-12-11 Ascendis Pharma As Long-acting polymeric prodrugs of exendin
SI2173890T1 (sl) 2007-06-21 2011-06-30 Univ Muenchen Tech Biološko aktivni proteini, ki imajo povečano in vivo in/ali in vitro stabilnost
BRPI0906643A2 (pt) 2008-02-01 2019-09-10 Ascendis Pharma As profármaco compreendendo um conjugado fármaco-ligante
EP2113256A1 (en) * 2008-04-29 2009-11-04 Ascendis Pharma AS PEGylated rhGH compounds
HUE029926T2 (en) * 2008-04-29 2017-04-28 Ascendis Pharma Growth Disorders Div As Pegylated recombinant human growth hormone compounds
DK2119726T5 (en) 2008-05-14 2018-03-26 Immatics Biotechnologies Gmbh Novel and powerful MHC class II peptides derived from survivin and neurocan
EP2403537A1 (en) 2009-03-05 2012-01-11 Ascendis Pharma A/S Interferon alpha carrier prodrugs
WO2011003234A1 (zh) 2009-07-08 2011-01-13 深圳市掌网立体时代视讯技术有限公司 光学立体放映装置、系统及方法
HUE052816T2 (hu) 2009-07-31 2021-05-28 Ascendis Pharma As Biológiailag lebontható polietilénglikol bázisú vízoldható hidrogélek
EP2459227B1 (en) 2009-07-31 2021-03-17 Ascendis Pharma A/S Prodrugs containing an aromatic amine connected by an amide bond to a carrier
RU2012129674A (ru) 2009-12-15 2014-01-27 Аспендис Фарма Ас Композиция гормона роста
EP4450523A3 (en) 2010-04-02 2025-03-12 Amunix Pharmaceuticals, Inc. Binding fusion proteins, binding fusion protein-drug conjugates, xten-drug conjugates and methods of making and using same
CA2794614C (en) 2010-05-21 2020-12-15 Xl-Protein Gmbh Biosynthetic proline/alanine random coil polypeptides and their uses
JP2015536314A (ja) 2012-10-17 2015-12-21 ノヴォ・ノルディスク・ヘルス・ケア・アーゲー 成長ホルモン送達のための脂肪酸アシル化アミノ酸
WO2016079114A1 (en) 2014-11-18 2016-05-26 Ascendis Pharma Growth Disorders Division A/S Novel polymeric hgh prodrugs
EP3988083A1 (en) 2014-11-21 2022-04-27 Ascendis Pharma Endocrinology Division A/S Long-acting growth hormone dosage forms
WO2016109823A1 (en) 2015-01-02 2016-07-07 Amunix Operation Inc. Treatment of pediatric growth hormone deficiency with human growth hormone analogues
EP3934625A1 (en) * 2019-03-04 2022-01-12 Ascendis Pharma Endocrinology Division A/S Long-acting growth hormone dosage forms with superior efficacy to daily somatropin

Also Published As

Publication number Publication date
ES2947818T3 (es) 2023-08-21
FIC20220017I1 (fi) 2022-06-03
JP2022033787A (ja) 2022-03-02
JP2021020932A (ja) 2021-02-18
KR102608645B1 (ko) 2023-12-01
US10799563B2 (en) 2020-10-13
EP4218823A3 (en) 2023-11-15
RS61734B2 (sr) 2022-04-29
WO2016079114A1 (en) 2016-05-26
NO2022014I1 (no) 2022-05-12
AU2015348633A1 (en) 2017-05-18
RU2017121203A3 (el) 2019-05-30
CA2968282A1 (en) 2016-05-26
SG11201703870UA (en) 2017-06-29
LTPA2022506I1 (el) 2022-06-10
KR20170084267A (ko) 2017-07-19
NZ731779A (en) 2021-11-26
EP4218823A2 (en) 2023-08-02
JP7431355B2 (ja) 2024-02-14
US20170354716A1 (en) 2017-12-14
RS61734B1 (sr) 2021-05-31
JP7210683B2 (ja) 2023-01-23
NL301172I2 (nl) 2022-06-16
JP2023052300A (ja) 2023-04-11
US20200390864A1 (en) 2020-12-17
NL301172I1 (nl) 2022-04-29
PL3653227T6 (pl) 2022-04-19
US12133883B2 (en) 2024-11-05
EP3653227B1 (en) 2021-01-20
SI3653227T1 (sl) 2021-04-30
ES2864415T7 (es) 2022-05-12
AU2015348633B2 (en) 2020-10-22
IL251906B2 (en) 2024-04-01
PL3653227T3 (pl) 2021-07-05
JP6783782B2 (ja) 2020-11-11
CY2022013I2 (el) 2023-01-05
KR20230152187A (ko) 2023-11-02
EP3237014A1 (en) 2017-11-01
EP3237014B1 (en) 2023-03-29
PT3653227T (pt) 2021-02-26
NZ769682A (en) 2024-09-27
DK3237014T5 (da) 2024-10-14
AU2015348633C1 (en) 2021-02-11
JP2017535609A (ja) 2017-11-30
DK3237014T3 (da) 2023-05-30
JP2024054177A (ja) 2024-04-16
MX2017006113A (es) 2017-10-16
AU2020270494B2 (en) 2024-02-01
BR112017009798A2 (pt) 2017-12-19
EP3653227B9 (en) 2023-03-08
ES2864415T9 (es) 2023-05-23
CY2022013I1 (el) 2023-01-05
AU2020270494A1 (en) 2020-12-17
IL307773A (en) 2023-12-01
MX2022009155A (es) 2022-08-16
JP6982156B2 (ja) 2021-12-17
FR22C1029I1 (fr) 2022-09-09
FI3237014T3 (fi) 2023-06-09
HUS2200019I1 (hu) 2022-06-28
RU2718664C2 (ru) 2020-04-13
DK3653227T3 (da) 2021-02-15
RU2017121203A (ru) 2018-12-19
HRP20210400T1 (hr) 2021-04-16
IL251906A0 (en) 2017-06-29
HUE053855T2 (hu) 2021-07-28
HRP20210400T4 (hr) 2022-04-29
US20250032587A1 (en) 2025-01-30
EP3653227A1 (en) 2020-05-20
FR22C1029I2 (fr) 2023-04-14
IL251906B1 (en) 2023-12-01
LUC00256I2 (el) 2025-03-04
AU2024201227A1 (en) 2024-03-28
EP3653227B3 (en) 2022-03-09
ES2864415T3 (es) 2021-10-13
LT3653227T (lt) 2021-03-25
SMT202100172T1 (it) 2021-05-07
DK3653227T6 (da) 2022-04-11
BR112017009798A8 (pt) 2020-11-03
SG10202105511RA (en) 2021-07-29
DK3653227T5 (da) 2023-08-21

Similar Documents

Publication Publication Date Title
CY1123963T1 (el) Καινοτομα πολυμερικα προφαρμακα hgh
CY1124959T1 (el) Αναστολεις λυσινης ειδικης απομεθυλασης-1
CY1123595T1 (el) Παραγωγα χολικου οξεος ως αγωνιστες fxr/tgr5
CY1124368T1 (el) Μεθοδοι αυξησης της τονικης αναστολης και θεραπειας του συνδρομου angelman
CY1124407T1 (el) Ενωσεις αναστολεα αυτοταξινης
CY1122329T1 (el) Anti-siglec-8 αντισωματα και μeθοδοι χρhσεως αυτων
CL2017001204A1 (es) Derivados de 6-amino-7-biciclo-7-deaza-purina como inhibidores de la proteína quinasa
CY1125205T1 (el) Φαρμακευτικες συνθεσεις δραστικων απο θεραπευτικη αποψη ενωσεων
EA201890725A1 (ru) Агонисты фарнезоидного х-рецептора и их применение
BR112017001796A2 (pt) composições de flagelina e seus usos
CY1125150T1 (el) Ενωσεις φαινυλο-2-υδροξυ-ακετυλαμινο-2-μεθυλο-φαινυλιου
GB2541571A (en) Pharmaceutical compositions
CO2017005038A2 (es) Composicones y métodos de tratamiento con profármacos de tizoxanida, un análogo o sal de la misma
CY1123366T1 (el) Παραγωγα 8-αμινο-2-οξο-1,3-διαζα-σπειρο-[4.5]-δeκανιου
CY1122818T1 (el) Παραγωγα 3-((ετερο-)αρυλ)-αλκυλ-8-αμινο-2-οξο-1,3-διαζα- σπε1ρο-[4.5]-δεκανιου
CY1123216T1 (el) Αναστολεις της gls1 για την αντιμετωπιση νοσων
EP3581183A4 (en) PHARMACEUTICAL COMPOSITION FOR ONCOTHERAPY
EA201791454A1 (ru) Лекарственные формы для трансдермального введения
CY1122882T1 (el) Παραγωγα 3-(καρβοξυαιθυλ)-8-αμινο-2-οξο-1,3-διαζα-σπειρο-[4.5]-δεκανιου
EP3672587A4 (en) PHARMACEUTICAL COMPOSITIONS INTENDED FOR THE TREATMENT OF OPHTHALMIC DISORDERS
CY1122923T1 (el) Παραγωγα 3-((ετερο-)αρυλ)-8-αμινο-2-οξο-1,3-διαζα-σπειρο-[4.5]-δεκανιου
CY1125014T1 (el) Υποκατεστημενα παραγωγα ξανθινης
EA201692111A1 (ru) Фармацевтические композиции, содержащие данириксин, для лечения инфекционных заболеваний
EA201892475A1 (ru) Оксабороловые сложные эфиры, их применение
PH12017500602A1 (en) Methods for treating ocular conditions